Fresenius SE KGaA Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Fresenius SE KGaA is gedaald met een gemiddeld jaarlijks percentage van -25.1%, terwijl de winst van de Healthcare -industrie jaarlijks groeide met 10.6%. De inkomsten zijn daalde met een gemiddeld percentage van 13.1% per jaar.

Belangrijke informatie

-25.1%

Groei van de winst

-25.3%

Groei van de winst per aandeel

Healthcare Groei van de industrie	15.7%
Inkomstengroei	-13.1%
Rendement op eigen vermogen	1.8%
Nettomarge	-2.1%
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

With Fresenius SE & Co. KGaA (ETR:FRE) It Looks Like You'll Get What You Pay For

May 02

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

Mar 29

Fresenius SE KGaA (ETR:FRE) Could Be At Risk Of Shrinking As A Company

Mar 13

Why Fresenius SE & Co. KGaA (ETR:FRE) Could Be Worth Watching

Feb 06

A Look At The Fair Value Of Fresenius SE & Co. KGaA (ETR:FRE)

Jan 19

Fresenius SE & Co. KGaA's (ETR:FRE) Shares Not Telling The Full Story

Jan 03

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

Nov 28

Fresenius SE & Co. KGaA (ETR:FRE) Analysts Just Trimmed Their Revenue Forecasts By 34%

Nov 10

Fresenius SE KGaA (ETR:FRE) Is Reinvesting At Lower Rates Of Return

Oct 27

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Sep 03

Some Investors May Be Worried About Fresenius SE KGaA's (ETR:FRE) Returns On Capital

Jul 25

We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

Jun 19

At €25.59, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Jun 01

Capital Allocation Trends At Fresenius SE KGaA (ETR:FRE) Aren't Ideal

Apr 18

Fresenius SE KGaA's (ETR:FRE) Soft Earnings Are Actually Better Than They Appear

Mar 13

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

Mar 10

Are Investors Undervaluing Fresenius SE & Co. KGaA (ETR:FRE) By 38%?

Feb 23

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Feb 08

The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Jan 03

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

Nov 28

Should You Investigate Fresenius SE & Co. KGaA (ETR:FRE) At €21.71?

Oct 23

The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Oct 01

Is Fresenius SE KGaA (ETR:FRE) Using Too Much Debt?

Aug 07

Is It Time To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Jul 20

Fresenius SE KGaA (ETR:FRE) May Have Issues Allocating Its Capital

Jul 02

Fresenius SE KGaA (ETR:FRE) Is Increasing Its Dividend To €0.92

Apr 28

At €34.09, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Apr 17

Fresenius SE KGaA (ETR:FRE) Is Paying Out A Larger Dividend Than Last Year

Apr 02

Fresenius SE KGaA (ETR:FRE) Could Be Struggling To Allocate Capital

Mar 27

Fresenius SE KGaA's (ETR:FRE) Upcoming Dividend Will Be Larger Than Last Year's

Feb 24

Opbrengsten en kosten

Hoe Fresenius SE KGaA geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

XTRA:FRE Opbrengsten, kosten en inkomsten (EUR Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	22,811	-479	3,178	615
30 Jun 24	22,632	721	3,203	615
31 Mar 24	22,417	420	3,173	604
31 Dec 23	22,299	353	3,155	608
30 Sep 23	21,361	1,810	3,183	647
30 Jun 23	21,560	555	3,238	625
31 Mar 23	17,071	952	2,365	578
31 Dec 22	21,532	1,154	3,094	614
30 Sep 22	25,828	1,444	3,561	610
30 Jun 22	29,766	1,611	4,080	677
31 Mar 22	38,256	1,796	5,580	777
31 Dec 21	37,520	1,818	5,453	784
30 Sep 21	36,858	1,729	5,423	800
30 Jun 21	36,452	1,743	5,341	757
31 Mar 21	36,126	1,683	5,149	758
31 Dec 20	36,277	1,707	5,235	758
30 Sep 20	36,284	1,812	5,378	741
30 Jun 20	36,208	1,829	5,418	752
31 Mar 20	36,049	1,889	5,517	698
31 Dec 19	35,409	1,883	5,406	660
30 Sep 19	34,933	1,884	5,159	644
30 Jun 19	34,283	1,859	5,105	613
31 Mar 19	33,904	2,040	4,991	635
31 Dec 18	33,530	2,027	4,893	646
30 Sep 18	33,390	2,022	5,136	660
30 Jun 18	33,495	1,999	5,177	640
31 Mar 18	33,645	1,797	5,341	596
31 Dec 17	33,886	1,814	5,554	558
30 Sep 17	33,011	1,745	5,192	524
30 Jun 17	32,147	1,731	5,143	513
31 Mar 17	30,818	1,659	4,933	508
31 Dec 16	29,471	1,560	4,742	502
30 Sep 16	28,908	1,477	4,620	480
30 Jun 16	28,415	1,452	4,489	473
31 Mar 16	28,158	1,399	4,413	473
31 Dec 15	27,626	1,358	4,195	464
30 Sep 15	26,889	1,256	4,031	443
30 Jun 15	25,927	1,175	3,832	422
31 Mar 15	24,502	1,136	3,533	394
31 Dec 14	23,231	1,067	3,359	369
30 Sep 14	22,010	1,094	3,170	359
30 Jun 14	21,077	1,083	3,057	351
31 Mar 14	20,653	1,040	3,055	352
31 Dec 13	20,331	1,011	3,044	348

Kwaliteitswinsten: FRE is momenteel verliesgevend.

Groeiende winstmarge: FRE is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: FRE is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 25.1% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van FRE over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: FRE is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Healthcare industrie ( 40.5% ).

Rendement op eigen vermogen

Hoge ROE: FRE heeft een negatief Return on Equity ( 1.85% ), omdat het momenteel verliesgevend is.

Fresenius SE KGaA Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

First quarter 2024 earnings released: EPS: €0.49 (vs €0.61 in 1Q 2023)

Fresenius SE & Co. KGaA to Report Fiscal Year 2023 Final Results on Mar 14, 2024

Third quarter 2023 earnings released: €0.72 loss per share (vs €0.57 profit in 3Q 2022)

Fresenius SE & Co. KGaA to Report Q2, 2024 Results on Jul 31, 2024

Recent updates

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

PAI Mid-Market Fund SCSp. managed by PAI Partners completed the acquisition of 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA (XTRA:FRE).

Fresenius SE KGaA (ETR:FRE) Is Finding It Tricky To Allocate Its Capital

Is There Now An Opportunity In Fresenius SE & Co. KGaA (ETR:FRE)?

Investors Still Waiting For A Pull Back In Fresenius SE & Co. KGaA (ETR:FRE)

Consensus EPS estimates fall by 34%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

Fresenius SE KGaA (ETR:FRE) Has Some Difficulty Using Its Capital Effectively

At €29.20, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

First quarter 2024 earnings released: EPS: €0.49 (vs €0.61 in 1Q 2023)

PAI Mid-Market Fund SCSp. managed by PAI Partners agreed to acquire 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA (XTRA:FRE).

With Fresenius SE & Co. KGaA (ETR:FRE) It Looks Like You'll Get What You Pay For

Verme family with other shareholders completed the acquisition of additional 70% stake in Clinica Ricardo Palma S.A. from Fresenius SE & Co. KGaA (XTRA:FRE).

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

New major risk - Financial position

Fresenius SE KGaA (ETR:FRE) Could Be At Risk Of Shrinking As A Company

Consensus EPS estimates fall by 11%

Why Fresenius SE & Co. KGaA (ETR:FRE) Could Be Worth Watching

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC completed the acquisition of EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE).

Consensus EPS estimates fall by 15%

Consensus EPS estimates fall by 15%

German Fresenius Reportedly Seeks to Sell Vamed Reha

Consensus EPS estimates fall by 20%

Consensus EPS estimates fall by 20%

A Look At The Fair Value Of Fresenius SE & Co. KGaA (ETR:FRE)

Fresenius SE & Co. KGaA's (ETR:FRE) Shares Not Telling The Full Story

Fresenius SE & Co. KGaA to Report Fiscal Year 2023 Final Results on Mar 14, 2024

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

Consensus EPS estimates increase by 57%

Fresenius SE & Co. KGaA (ETR:FRE) Analysts Just Trimmed Their Revenue Forecasts By 34%

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC agreed to acquire EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE) for €500 million.

Third quarter 2023 earnings released: €0.72 loss per share (vs €0.57 profit in 3Q 2022)

Consensus revenue estimates decrease by 46%

Fresenius SE & Co. KGaA to Report Q2, 2024 Results on Jul 31, 2024

Fresenius SE KGaA (ETR:FRE) Is Reinvesting At Lower Rates Of Return

KKR in Talks to Buy Eugin from Fresenius

Fresenius Reportedly Plans to Offload Digital Subsidiary Curalie

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Consensus EPS estimates fall by 14%

New major risk - Financial position

Second quarter 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates increase by 14%

Fresenius SE & Co. KGaA to Report Q3, 2023 Results on Nov 02, 2023

Some Investors May Be Worried About Fresenius SE KGaA's (ETR:FRE) Returns On Capital

We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

At €25.59, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Fresenius Se & Co. Kgaa Proposes Dividend for 2022

Upcoming dividend of €0.92 per share at 3.3% yield

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Fresenius SE & Co. KGaA to Report Q1, 2023 Results on May 09, 2023

Capital Allocation Trends At Fresenius SE KGaA (ETR:FRE) Aren't Ideal

Consensus EPS estimates fall by 17%

Fresenius SE KGaA's (ETR:FRE) Soft Earnings Are Actually Better Than They Appear

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

Full year 2022 earnings: EPS misses analyst expectations

Are Investors Undervaluing Fresenius SE & Co. KGaA (ETR:FRE) By 38%?

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Fresenius SE & Co. KGaA, Annual General Meeting, May 17, 2023

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

QIC Reportedly Set to Clinch Healius Day Hospital Unit for $140 Million Plus

Third quarter 2022 earnings released: EPS: €0.57 (vs €0.74 in 3Q 2021)

Should You Investigate Fresenius SE & Co. KGaA (ETR:FRE) At €21.71?

Brookfield Reportedly Drops Out of Race to Buy Healius

The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Fresenius SE Announces Chief Financial Officer Changes

Fresenius SE & Co. KGaA Announces Michael Sen as CEO on October 1, 2022 Succeeding Stephan Sturm

Is Fresenius SE KGaA (ETR:FRE) Using Too Much Debt?